{"analyses":[{"ciLowerLimit":"0.36","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.52","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.44","statisticalComment":"The Log Rank Test was stratified by etiology of disease, geographic region, presence of extrahepatic spread of disease and/or macrovascular invasion.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.0","upperLimit":"5.5","value":"5.2"},{"groupId":"OG001","lowerLimit":"1.9","upperLimit":"1.9","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"470"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"description":"Duration of PFS is defined as the time of randomization to the earlier of the following events, progressive disease as determined by Investigator (per RECIST 1.0, which is defined by a ≥ 20% increase in the sum of the longest diameter of target lesions from baseline) or death due to any cause. A Kaplan- Meier analysis was performed to estimate the median duration.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cabozantinib (XL184) 60 mg tablet once daily\n\nCabozantinib tablets","id":"OG000","title":"Cabozantinib (XL184)"},{"description":"Oral cabozantinib-matched placebo tablet once daily\n\nPlacebo tablets","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"The prespecified primary analysis of PFS was based on the first 707 randomized subjects (470 cabozantinib, 237 placebo).","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}